Glimepiride/Pioglitazone Hydrochloride

格列美脲/盐酸吡格列酮

Report date: 2026/05/26 20:00:28

Base Information

Drug NameGlimepiride/Pioglitazone Hydrochloride
Drug Alias Name盐酸吡格列酮/格列美脲Pioglitazone Hydrochloride/Glimepiridepioglitazone hydrochloride and glimepiridepioglitazone and glimepirideSONIAS +[7] 
ClassificationSmall molecules
Mechanisms of ActionKATP channels blockersPeroxisome proliferator-activated receptor γ agonistsSulfonylurea receptor modulators
TargetsSulfonylurea receptorPeroxisome proliferator-activated receptor γKATP channels
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2006/07/28
Country/TerritoryUnited StatesEUMainland China +[4] 
CombinationsYes Pioglitazone HydrochlorideGlimepiride
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceuticals USA IncCheplapharm Arzneimittel GmbhTakeda Pharmaceutical Co Ltd +[5] 
Inactive CompaniesTianjin Remedy Research InstituteHebei Aier Haitai Pharmaceutical Co Ltd
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeA10BD06
Related LinksKEGG